<DOC>
	<DOCNO>NCT00698061</DOCNO>
	<brief_summary>Subjects respond previous hepatitis B vaccination vaccinate either adjuvanted HBV-MPL vaccine Engerix™-B vaccine accord three-dose vaccination schedule ( 0 , 1 , 2 month ) boost Month 12 per group allocation . The immunogenicity safety HBV-MPL vaccine compare control vaccine , Engerix™-B .</brief_summary>
	<brief_title>Immunogenicity Safety Adjuvanted HBV Vaccine Compared Engerix™-B , Non-responder Population ≥ 15y</brief_title>
	<detailed_description>At time conduct study , sponsor GlaxoSmithKline know former name SmithKline Beecham .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>At study entry : A male female ≥ 15 year age time first vaccination . Free obvious health problem establish medical history clinical examination enter study . Written inform consent obtain subject . Documented nonresponse previous hepatitis B vaccination within 6 month receive full vaccination course ( i.e . ≥ 3 dos hepatitis B vaccine ) If subject female , must nonchildbearing potential , , childbearing potential , must abstinent use adequate contraceptive precaution one month prior enrollment two month last vaccination . Before booster dose month 12 : Additional write informed consent cover booster administration blood sample month 12 13 must obtain subject . If subject female , must nonchildbearing potential , , childbearing potential , must abstinent use adequate contraceptive precaution one month prior two month administration booster dose Use investigational nonregistered drug vaccine study vaccine ( ) study period within 30 day precede first dose study vaccine . Planned administration/ administration vaccine foreseen study protocol period start 30 day dose vaccine end 30 day . Known exposure hepatitis B within 6 week . History hepatitis B infection . Confirmed human immunodeficiency virus ( HIV ) infection . A family history congenital hereditary immunodeficiency . History allergic disease/reactions likely exacerbate component vaccine . Acute disease time enrollment . Hepatomegaly , right upper quadrant abdominal pain tenderness . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration/ administration study period . Pregnant lactate female .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>Adjuvanted vaccine</keyword>
</DOC>